Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer Cold Genesys is a clinical-stage company focusing on the development of oncolytic viruses and immunotherapies against cancer.
Cold Genesys, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cold-genesys” connections=”true” suffix=””]
Oncolytic virus technology utilizes adenoviruses, engineered to selectively replicate in targeted cancer cells resulting in targeted
cancer cell death. They are also programmed to express a human GM-CSF gene, which stimulates natural immune cells to promote a tumor-specific T cell response against tumors after oncolysis.
In 2010, Cold Genesys, acquired proprietary Oncolytic virus technology and the worldwide rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). In exchange for this, BioSante received a 19.9% ownership position in Cold Genesys.
In Aug 2015, Cold Genesys raised $10 Mn in a Series B co-led by Ally Bridge Group and WI Harper Group with participation from Whitesun Healthcare Ventures and Song Hong Fang.
In July 2014, Cold Genesys raised $13.57 Mn in a Series A Round of financing to accelerate Its ongoing Phase II/III Clinical Trial for Bladder Cancer. It was financially backed by Ally Bridge Group.